cash flow positive

Pharming Group's Q1 2026 revenues fell 8% YoY to $72.4M, hurt by RUCONEST decline, but Joenja surged 34%. Company maintains full-year guidance and advances international launches.

Amarin reports Q1 2026 revenue of $45.1M (up 7%), narrows operating losses 33%, maintains debt-free balance with $307.8M cash.

Tevogen Bio announces capital discipline measures including lead investor holding commitment, restricting share issuance to 1% of authorized shares, and targeting $50M+ revenue acquisitions.

Unusual Machines stock surged 7% after doubling 2025 revenue guidance to $11.2M and projecting positive operating cash flow by 2026, bolstered by $142M cash and zero debt.

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.

Interactive Strength acquiring Ergatta for up to $19.5M to expand subscription revenue. Combined 2026 revenue projected to exceed $30M, with Ergatta contributing over $10M.